SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?


To: golfer72 who wrote (1428521)12/13/2023 1:52:00 PM
From: Maple MAGA 1 Recommendation

Recommended By
Mick Mørmøny

  Respond to of 1578094
 
Italian Vax Promoter Investigated For Fraudulent Misrepresentation and Murder

Posted on December 12, 2023 by Baron Bodissey



Former Italian Minister of Health Roberto Speranza is being officially investigated by the prosecutor’s office in Rome for his actions in promoting the experimental mRNA treatment intended to mitigate the effects of infection with the Wuhan Coronavirus.

Many thanks to HeHa for translating this video report, and to Vlad Tepes and RAIR Foundation for the subtitling:

Video transcript:

00:00 We have now reached an absolutely relevant percentage
00:05 of vaccinated people in Italy: 89.41%.
00:10 Here is former Minister of Health Roberto Speranza, when he proudly
00:14 announced the vaccination data in Italy.
00:17 So at this moment in Italy, just a bit more than 10% of people are unvaccinated.
00:23 Well, today Roberto Speranza is being investigated for the lies he allegedly told about vaccines.
00:28 Fraudulent misrepresentation and murder are among the crimes they are challenging him with.
00:33 Look, this is the document that we are disclosing to you tonight, exclusively.
00:36 It is written that former Minister Roberto Speranza, and Nicola Magrini,
00:40 former general director of AIFA [Italy’s Medicines Agency],
00:43 have been both registered as investigated suspects
00:47 by the Prosecutor’s Office of Rome.